Black Diamond’s 2025 Annual Stockholders Meeting Highlights

An update from Black Diamond Therapeutics ( (BDTX) ) is now available.

On June 12, 2025, Black Diamond Therapeutics held its 2025 Annual Meeting of Stockholders virtually, where a quorum was established with 42,988,581 shares present. During the meeting, stockholders elected three Class II directors and ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (BDTX) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Black Diamond Therapeutics stock, see the BDTX Stock Forecast page.

Spark’s Take on BDTX Stock

According to Spark, TipRanks’ AI Analyst, BDTX is a Underperform.

Black Diamond Therapeutics is currently a high-risk investment due to its weak financial performance characterized by zero revenue and negative cash flow. The technical analysis suggests continued volatility, and the valuation highlights typical challenges of early-stage biotech firms. However, the recent strategic partnership with Servier offers potential long-term benefits. The overall score reflects the significant financial challenges and current market sentiment, with potential upside from successful execution of its strategic initiatives.

To see Spark’s full report on BDTX stock, click here.

More about Black Diamond Therapeutics

Black Diamond Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of targeted therapies for genetically defined cancers.

Average Trading Volume: 3,501,987

Technical Sentiment Signal: Sell

Current Market Cap: $139.9M

See more data about BDTX stock on TipRanks’ Stock Analysis page.